ReViral gets a $55M booster shot of cash as it expands its development work on an RSV treatment
Six months after ReViral outlined the efficacy of their respiratory syncytial virus, or RSV, treatment in healthy adults with an intranasal infection, the London-based biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
